Copyright 2024
| PMID | Allele | Disease | Population | Drug Names | SNP | Class | Sentence |
|---|---|---|---|---|---|---|---|
| 30538833 | HLA-DRB1*15 | metabolic syndrome | NA | NA | rs738409 | positive | |
| we found class i and ii hla antigens hla a24, hla b15, hla dr15, hla dr16, hla dq3 and hla dq5 more frequent in subjects with hepatic steatosis without any other risk factor and hla-a2, hla-32, hla b18, hla b49 and hla b53 in patients with obesity or metabolic syndrome. | |||||||
| 30538833 | HLA-DQB1*05 | metabolic syndrome | NA | NA | rs738409 | positive | |
| we found class i and ii hla antigens hla a24, hla b15, hla dr15, hla dr16, hla dq3 and hla dq5 more frequent in subjects with hepatic steatosis without any other risk factor and hla-a2, hla-32, hla b18, hla b49 and hla b53 in patients with obesity or metabolic syndrome. | |||||||
| 30538833 | HLA-DRB1*16 | metabolic syndrome | NA | NA | rs738409 | positive | |
| we found class i and ii hla antigens hla a24, hla b15, hla dr15, hla dr16, hla dq3 and hla dq5 more frequent in subjects with hepatic steatosis without any other risk factor and hla-a2, hla-32, hla b18, hla b49 and hla b53 in patients with obesity or metabolic syndrome. | |||||||
| 30538833 | HLA-B*15 | metabolic syndrome | NA | NA | rs738409 | positive | |
| we found class i and ii hla antigens hla a24, hla b15, hla dr15, hla dr16, hla dq3 and hla dq5 more frequent in subjects with hepatic steatosis without any other risk factor and hla-a2, hla-32, hla b18, hla b49 and hla b53 in patients with obesity or metabolic syndrome. | |||||||
| 30538833 | HLA (HLA) | non-alcoholic fatty liver disease | NA | NA | rs738409 | unclassified | |
| purposethe aim of our study was to identify the possible involvement of adiponutrine polymorphysm and of human leukocyte antigens (hla) in the development of non-alcoholic fatty liver disease (nafld).material and we included in this study a total of 138 subjects with non-invasive diagnosis of non-alcoholic hepatic steatosis. | |||||||
| 30538833 | HLA (HLA) | non-alcoholic fatty liver disease | NA | NA | rs738409 | only_studied | |
| regarding histocompatibility antigens, we studied for the first time in our country the relationship between hla and non-alcoholic fatty liver disease. | |||||||
| 32085385 | HLA (HLA) | metabolic syndrome | NA | NA | NA | unclassified | |
| male wistar rats were fed either a corn starch diet (c) or high-carbohydrate high-fat diet (h) with either 20% beef tallow or sfa (lauric (hla), myristic (hma), palmitic (hpa) or stearic (hsa) acids) for 16 weeks prior to and 8 weeks after excision of the medial meniscus of right knee joint to initiate oa when pain behaviour, glial activity, progression of knee oa, inflammatory mediators and signs of metabolic syndrome were assessed. | |||||||
| 34589554 | HLA-C*06 | rs492602 | Chinese Han | rs281379 | rs2247056 | positive | |
| NA | |||||||
| 32815445 | HLA-B*27 | plantar fasciitis | NA | colchicine | NA | unclassified | |
| plantar fasciitis was more common and hla-b27 positivity rate was lower in the fmf/jspa group (or:0.08, p = .024), (or:4.71, p = .002) compared to jspa. | |||||||
| 11853408 | HLA-B*35 | yellow fever | NA | NA | NA | unclassified | |
| human cytotoxic t lymphocyte responses to live attenuated 17d yellow fever vaccine: identification of hla-b35-restricted ctl epitopes on nonstructural proteins ns1, ns2b, ns3, and the structural protein e. yellow fever virus (yfv) is a re-emerging problem despite the existence of an effective live-attenuated vaccine. | |||||||
Copyright 2024